pirfenidone has been researched along with Cancer of Lung in 29 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 14 (48.28) | 24.3611 |
| 2020's | 15 (51.72) | 2.80 |
| Authors | Studies |
|---|---|
| Ishibashi, F; Mizobuchi, T; Nagato, K; Saiki, A; Sugano, I; Tsuyusaki, J | 1 |
| Antunes, C; Branco, H; Oliveira, J; Santos, LL; Vasconcelos, MH; Xavier, CPR | 1 |
| Cao, L; Deng, P; Hu, C; Li, Y; Liu, J; Pan, P; Yang, H | 1 |
| Cai, M; Chen, J; Chen, Y; Guo, Y; Huang, J; Huang, W; Lai, M; Liang, L; Lin, L; Liu, M; Xie, L; Zhang, X; Zhang, Y; Zhu, K | 1 |
| Didiasova, M; Drakopanagiotakis, F; Krämer, M; Mamazhakypov, A; Markart, P; Schaefer, L; Wygrecka, M | 1 |
| Imanishi, N; Kanayama, M; Kuroda, K; Kuwata, T; Matsumiya, H; Mori, M; Shinohara, S; Taira, A; Tanaka, F; Yoneda, K | 1 |
| Aokage, K; Ishii, G; Miyoshi, T; Sekihara, K; Tane, K; Tsuboi, M | 1 |
| Boulate, D; Crutu, A; Dauriat, G; Dolidon, S; Fabre, D; Fadel, E; Feuillet, S; Florea, V; Gazengel, P; Hanna, A; Le Pavec, J; Mercier, O; Mitilian, D; Mussot, S; Pradere, P | 1 |
| Fujiwara, A; Fukui, E; Funaki, S; Kanou, T; Kimura, K; Minami, M; Ose, N; Shintani, Y | 1 |
| Akazawa, Y; Ishijima, M; Kanazu, M; Kuge, T; Mori, M; Okabe, F; Uenami, T; Yamaguchi, T; Yamamoto, Y; Yano, Y | 1 |
| Asano, K; Enokida, K; Hattori, S; Hayama, N; Hirabayashi, K; Horio, Y; Ito, Y; Miyaoka, M; Niimi, K; Oguma, T; Ohshinden, K; Takahashi, F; Takahashi, G; Takahashi, M; Takiguchi, H; Takihara, T; Tanaka, J | 1 |
| Han, H; Huang, Y; Kang, Y; Li, L; Liu, B; Liu, C; Qin, W; Tang, Y; Yuan, X; Zhao, W; Zou, J | 1 |
| Deng, H; Fang, T; Shen, Q; Xu, Y; Yang, J; Yang, Y; Zhang, J; Zuo, T | 1 |
| Cheng, X; Han, X; Li, J; Yu, H; Yu, L; Zhang, X | 1 |
| Miao, K; Tian, X; Xu, W; Xu, Y; Zhang, L; Zhang, Y | 1 |
| Maeda, S | 1 |
| Azuma, A; Gemma, A; Inomata, M; Miura, Y; Nei, T; Saito, T; Saito, Y; Takoi, H; Tanaka, T; Yatagai, Y | 1 |
| Tanino, Y | 1 |
| Joensuu, E; Koli, K; Li, C; Myllärniemi, M; Rezov, V; Rönty, M; Vartiainen, V; Yin, M | 1 |
| Azuma, A; Bando, M; Date, H; Ebina, M; Fukuoka, J; Gemma, A; Goto, Y; Hasegawa, Y; Hattori, N; Homma, S; Inase, N; Inoue, Y; Ishii, Y; Izumi, S; Johkoh, T; Kido, T; Kishaba, T; Kishi, K; Miyamoto, A; Mukae, H; Nakayama, T; Nishioka, Y; Ogura, T; Sakamoto, S; Sasaki, S; Suda, T; Sugino, K; Taguchi, Y; Takahashi, H; Takahashi, K; Taniguchi, H; Watanabe, K; Yokoyama, A; Yoshino, I | 1 |
| Ballester, B; Cortijo, J; Milara, J | 1 |
| Katayama, Y; Komada, T; Kusagawa, H; Shomura, S | 1 |
| Kang, S | 1 |
| Iwata, T; Mizobuchi, T; Nagato, K; Nakajima, T; Nakatani, Y; Ota, S; Suzuki, H; Tagawa, T; Yoshida, S; Yoshino, I | 1 |
| Kunii, E; Moriyama, S; Niimi, A; Ohkubo, H | 1 |
| Asato, Y; Azuma, A; Chida, M; Fukuoka, J; Hiroshima, K; Ikeda, N; Iwasawa, T; Iwata, T; Katakami, N; Kuwano, K; Matsuura, M; Mitsudomi, T; Nakagawa, K; Nakanishi, Y; Okada, M; Okami, J; Okubo, K; Sakai, S; Sakamoto, K; Tada, H; Takenoyama, M; Tomii, K; Tsuboi, M; Yamashita, M; Yamashita, Y; Yokouchi, H; Yoshida, S; Yoshimura, K; Yoshino, I | 1 |
| Fujiwara, T; Iwata, T; Nakajima, T; Suzuki, H; Wada, H; Yoshida, S; Yoshino, I | 1 |
| Le, A; Takai, K; Weaver, VM; Werb, Z | 1 |
| Fujiwara, A; Funaki, S; Kawamura, T; Kimura, T; Minami, M; Okumura, M; Shintani, Y | 1 |
5 review(s) available for pirfenidone and Cancer of Lung
| Article | Year |
|---|---|
Lung transplantation for idiopathic pulmonary fibrosis.
Topics: Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Comorbidity; Disease Progression; Frailty; Gastroesophageal Reflux; Humans; Hypertension, Pulmonary; Idiopathic Interstitial Pneumonias; Idiopathic Pulmonary Fibrosis; Indoles; Lung Neoplasms; Lung Transplantation; Prognosis; Pyridones; Telomere Shortening | 2020 |
[A Case Report of Checkpoint Inhibitor Pneumonitis Caused by PD-1
Antibody-Safety and Effectiveness of Pirfenidone].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Carcinoma, Squamous Cell; Glucocorticoids; Humans; Immune Checkpoint Inhibitors; Indoles; Lung Neoplasms; Male; Nivolumab; Pneumonia; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Pyridones; Quinolines; Retrospective Studies | 2021 |
[Perioperative Management of Patients with Pulmonary Comorbidities Undergoing Lung Resection].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Comorbidity; Glucocorticoids; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Methylprednisolone; Perioperative Care; Pneumonectomy; Postoperative Complications; Pulmonary Disease, Chronic Obstructive; Pyridones; Respiratory Insufficiency | 2017 |
Japanese guideline for the treatment of idiopathic pulmonary fibrosis.
Topics: Acetylcysteine; Administration, Inhalation; Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Disease Progression; Drug Therapy, Combination; Evidence-Based Medicine; Glycine; Humans; Idiopathic Pulmonary Fibrosis; Immunosuppressive Agents; Indoles; Japan; Lung Neoplasms; Meta-Analysis as Topic; Practice Guidelines as Topic; Prognosis; Pyridones; Quality of Health Care; Sulfonamides; Survival Rate | 2018 |
Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung Neoplasms; Myofibroblasts; Pyridones | 2019 |
1 trial(s) available for pirfenidone and Cancer of Lung
| Article | Year |
|---|---|
A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE Study).
Topics: Administration, Oral; Disease Progression; Drug Administration Schedule; Humans; Idiopathic Pulmonary Fibrosis; Japan; Lung Neoplasms; Pneumonectomy; Pyridones; Risk Factors; Time Factors; Treatment Outcome | 2016 |
23 other study(ies) available for pirfenidone and Cancer of Lung
| Article | Year |
|---|---|
Uniportal video-assisted thoracic surgery and perioperative pirfenidone for lung cancer and idiopathic pulmonary fibrosis: a case report.
Topics: Aged; Female; Humans; Idiopathic Pulmonary Fibrosis; Lung Neoplasms; Neoplasm Recurrence, Local; Pyridones; Thoracic Surgery, Video-Assisted | 2021 |
Pirfenidone Sensitizes NCI-H460 Non-Small Cell Lung Cancer Cells to Paclitaxel and to a Combination of Paclitaxel with Carboplatin.
Topics: Antineoplastic Agents; Apoptosis; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Humans; Lung Neoplasms; Paclitaxel; Pyridones | 2022 |
Pirfenidone promotes the levels of exosomal miR-200 to down-regulate ZEB1 and represses the epithelial-mesenchymal transition of non-small cell lung cancer cells.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MicroRNAs; Neoplasm Invasiveness; Pyridones; Tumor Microenvironment; Zinc Finger E-box-Binding Homeobox 1 | 2022 |
Inhibition of CEMIP potentiates the effect of sorafenib on metastatic hepatocellular carcinoma by reducing the stiffness of lung metastases.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Humans; Hyaluronoglucosaminidase; Liver Neoplasms; Lung Neoplasms; Signal Transduction; Sorafenib; Tumor Microenvironment | 2023 |
Pirfenidone inhibits motility of NSCLC cells by interfering with the urokinase system.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Humans; Indoleacetic Acids; Lung Neoplasms; Membrane Proteins; Plasminogen Activator Inhibitor 1; Pyridones; Tumor Microenvironment; Urokinase-Type Plasminogen Activator | 2020 |
Perioperative pirfenidone treatment for lung cancer patients with idiopathic pulmonary fibrosis.
Topics: Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Lung Neoplasms; Perioperative Care; Postoperative Period; Pyridones; Retrospective Studies; Treatment Outcome | 2020 |
Perioperative pirfenidone treatment as prophylaxis against acute exacerbation of idiopathic pulmonary fibrosis: a single-center analysis.
Topics: Aged; Aged, 80 and over; Disease Progression; Female; Follow-Up Studies; Humans; Idiopathic Pulmonary Fibrosis; Lung Neoplasms; Male; Middle Aged; Negative Results; Patient Selection; Perioperative Care; Postoperative Complications; Prognosis; Pyridones; Survival Rate | 2020 |
Effects of pirfenidone targeting the tumor microenvironment and tumor-stroma interaction as a novel treatment for non-small cell lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; Cell Line, Tumor; Culture Media, Conditioned; Fibroblasts; Humans; Lung Neoplasms; Mice; Mice, Nude; Myofibroblasts; Pyridones; Stromal Cells; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2020 |
Safety and effectiveness of pirfenidone combined with carboplatin-based chemotherapy in patients with idiopathic pulmonary fibrosis and non-small cell lung cancer: A retrospective cohort study.
Topics: Aged; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Female; Humans; Idiopathic Pulmonary Fibrosis; Immune Checkpoint Inhibitors; Lung Neoplasms; Male; Middle Aged; Pyridones; Retrospective Studies | 2020 |
Regression of Lung Squamous Cell Carcinoma after the Withdrawal of Cyclosporin A Combined with Pirfenidone Treatment in a Patient with Idiopathic Pulmonary Fibrosis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Carcinoma, Squamous Cell; Cyclosporine; Humans; Idiopathic Pulmonary Fibrosis; Lung; Lung Neoplasms; Male; Pyridones; Treatment Outcome | 2021 |
Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in mice.
Topics: Animals; B7-H1 Antigen; Humans; Idiopathic Pulmonary Fibrosis; Lung Neoplasms; Mice; Pyridones | 2020 |
Multifunctional ZnO@CuS nanoparticles cluster synergize chemotherapy and photothermal therapy for tumor metastasis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Copper; Doxorubicin; Female; Humans; Lung Neoplasms; Metal Nanoparticles; Mice; Mice, Inbred BALB C; Photothermal Therapy; Pyridones; Sulfides; Xenograft Model Antitumor Assays; Zinc Oxide | 2021 |
Treatment of steroid-resistant checkpoint inhibitor pneumonitis with pirfenidone: A case report.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Carcinoma, Non-Small-Cell Lung; Drug-Related Side Effects and Adverse Reactions; Humans; Lung Neoplasms; Male; Pneumonia; Pyridones | 2021 |
Reduced incidence of lung cancer in patients with idiopathic pulmonary fibrosis treated with pirfenidone.
Topics: Aged; Antineoplastic Agents; Emphysema; Female; Humans; Idiopathic Pulmonary Fibrosis; Incidence; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Pyridones; Retrospective Studies; Risk; Vital Capacity | 2018 |
Does pirfenidone have anticancer effects in patients with idiopathic pulmonary fibrosis?
Topics: Antineoplastic Agents; Female; Humans; Idiopathic Pulmonary Fibrosis; Incidence; Lung Neoplasms; Male; Prognosis; Pyridones | 2018 |
Pirfenidone decreases mesothelioma cell proliferation and migration via inhibition of ERK and AKT and regulates mesothelioma tumor microenvironment in vivo.
Topics: Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Collagen; Extracellular Matrix; Female; Fibroblasts; Fibrosis; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mesothelioma; Mesothelioma, Malignant; Mice; Mice, Inbred BALB C; Proto-Oncogene Proteins c-akt; Pyridones; Signal Transduction; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2018 |
[Successful resection of lung cancer with idiopathic pulmonary fibrosis treated by pirfenidone during perioperative period].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; Humans; Idiopathic Pulmonary Fibrosis; Lung Neoplasms; Male; Perioperative Period; Pyridones | 2013 |
2014 American Thoracic Society International Conference.
Topics: Acetylcysteine; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Asthma; Congresses as Topic; Eosinophilia; Expectorants; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Idiopathic Pulmonary Fibrosis; Indoles; Lung Neoplasms; Protein Kinase Inhibitors; Pulmonary Disease, Chronic Obstructive; Pyridones; Respiratory Distress Syndrome | 2014 |
Experience with perioperative pirfenidone for lung cancer surgery in patients with idiopathic pulmonary fibrosis.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Disease Progression; Feasibility Studies; Female; Humans; Idiopathic Pulmonary Fibrosis; Lung Neoplasms; Male; Middle Aged; Perioperative Care; Postoperative Complications; Pyridones; Retrospective Studies; Treatment Outcome | 2015 |
Efficacy of combined corticosteroid and pirfenidone for acute exacerbation of idiopathic pulmonary fibrosis after surgery for lung cancer: a case report.
Topics: Acute-Phase Reaction; Aged, 80 and over; Disease Progression; Drug Therapy, Combination; Glucocorticoids; Humans; Idiopathic Pulmonary Fibrosis; Infusions, Intravenous; Lung Neoplasms; Male; Methylprednisolone; Postoperative Complications; Prednisolone; Pulse Therapy, Drug; Pyridones; Treatment Outcome | 2015 |
Effect of Perioperative Pirfenidone Treatment in Lung Cancer Patients With Idiopathic Pulmonary Fibrosis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Drug Administration Schedule; Drug Evaluation; Female; Humans; Idiopathic Pulmonary Fibrosis; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Perioperative Care; Pneumonectomy; Postoperative Complications; Pyridones; Retrospective Studies; Risk Assessment; Risk Factors; Smoking | 2016 |
Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer.
Topics: Animals; Antineoplastic Agents; Cancer-Associated Fibroblasts; Cell Line, Tumor; Cell Proliferation; Collagen; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Mice, Inbred BALB C; Molecular Targeted Therapy; Pyridones; Signal Transduction; Time Factors; Transforming Growth Factor beta; Triple Negative Breast Neoplasms; Tumor Burden; Tumor Cells, Cultured; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2016 |
Pirfenidone plays a biphasic role in inhibition of epithelial-mesenchymal transition in non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Epithelial-Mesenchymal Transition; Female; Fibroblasts; Humans; Lung Neoplasms; Mice; Phosphorylation; Pyridones; Signal Transduction; Smad2 Protein; Transforming Growth Factor beta1 | 2017 |